U.S. Food and Drug Administration Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

- Global market for liver cancer drugs is projected to exceed $2 billion in 2015

PETACH TIKVA, Israel, Sept. 17, 2015  -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the Company's drug candidate CF102 Fast Track designation as a second line treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer. CF102 had already received the FDA's Orphan Drug designation.

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for the First Phase 3 Clinical Trial of Its Proprietary Combination Regimen of TG-1101 (ublituximab) in Combination With TGR-1202 for Patients With Chronic Lymphocytic Leukemia (CLL)

Novel Design Allows for Simultaneous Approval of Two Investigational Agents in a Single Phase 3 Study Under SPA
Study Will Include Both Front-Line and Previously Treated Patients With CLL
Interim Analysis Following Completion of Enrollment Could be Used to Support Accelerated Approval of the Combination of TG-1101 +TGR-1202
International Phase 3 Study Entitled "UNITY-CLL" to be Led by John Gribben, MD, PhD of Barts Cancer Institute, London, UK

Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation

Combines Amgen's Proprietary Antibodies and Xencor's XmAb® Bispecific Antibody Platform to Develop New Therapeutic Candidates
Includes Xencor's Preclinical CD38 Bispecific T Cell Engager for Multiple Myeloma
Xencor to Receive $45 Million Upfront Payment and Up to $1.7 Billion in Clinical, Regulatory and Sales Milestone Payments in Total for Six Programs

THOUSAND OAKS, Calif. and MONROVIA, Calif., Sept. 16, 2015 -- Amgen (AMGN) and Xencor, Inc. (Xencor) (XNCR) announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb^® bispecific technology platform.